Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Prime Medicine, Inc. Common Stock(PRME)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PRME
09/24/2026: PRME (1-star) is currently NOT-A-BUY. Pass it for now.
Prime Medicine is a pre-revenue clinical-stage biotechnology company developing 'search-and-replace' gene editing therapies. Its primary strength lies in its proprietary Prime Editing platform, which aims to provide higher precision than existing CRISPR approaches. The investment story centers on the potential to cure serious genetic diseases; however, the company faces high risks, including the significant hurdle of proving clinical efficacy and the potential for long-term cash requirements. Investors should note the company's early development phase and high execution risk, which makes it suitable only for those comfortable with high volatility. Key developments to monitor include upcoming clinical trial data and potential pharmaceutical partnerships.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company represents a high-risk, high-reward growth play in the biotech sector contingent on clinical success. |
| Momentum investor | Mixed fit | Fits conditionally during periods of positive clinical trial news or sector-wide biotech momentum. |
| Value investor | Weak fit | The lack of revenue and earnings makes this unsuitable for traditional value investing criteria. |
| Dividend investor | Weak fit | The company is in an intensive cash-burning growth phase and does not pay dividends. |
| Low-risk investor | Weak fit | The company's clinical-stage status and high volatility present significant risks unsuited for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices are highly sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | Medium / high | Valuations are based on long-term potential rather than current fundamentals, making them susceptible to market re-ratings. |
| Competition risk (CRISPR-based therapies) | High | The sector is crowded with well-capitalized competitors developing similar gene-editing solutions. |
| Business quality | Medium | While the technology is novel, the company has yet to prove its commercial viability through successful product approvals. |
| Dividend income | Low / none | There is no expectation of dividend income as the company prioritizes R&D. |
| Execution risk | High | The complex nature of gene editing therapy development carries high failure rates at every stage of the clinical process. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -54.34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 556.83M USD | Price to earnings Ratio - | 1Y Target Price 7.11 |
Price to earnings Ratio - | 1Y Target Price 7.11 | ||
Volume (30-day avg) 2.9M shares | Beta 2.35 | 52 Weeks Range 2.67 - 6.94 | Updated Date 09/24/2026 |
52 Weeks Range 2.67 - 6.94 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic R&D | Potential future licensing and commercialization of gene-editing therapies. | The company earns no money today; it is betting on future revenue from successful medical treatments. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 622.86M | Price to Sales(TTM) 136.71 |
Enterprise Value 622.86M | Price to Sales(TTM) 136.71 | ||
Enterprise Value to Revenue 152.92 | Enterprise Value to EBITDA -3.1 | Shares Outstanding 181.38M | Shares Floating 112.25M |
Shares Outstanding 181.38M | Shares Floating 112.25M | ||
Percent Insiders 23.66 | Percent Institutions 70.97 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Prime Medicine, Inc. Common Stock
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2022-10-20 | CEO & Director Dr. Allan Reine M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 146 | Website https://primemedicine.com |
Full time employees 146 | Website https://primemedicine.com | ||
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.